CLINICAL_TRIALS
trial_result
· 2021-01-26
Clinical Trial Update: SHIP (Selinexor in Hormone Insensitive Prostate Cancer) [Phase 2]
Summary
Phase 2 trial SHIP investigating selinexor in hormone-insensitive prostate cancer was terminated; results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Karyopharm Therapeutics Inc | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-01-26